- Home
- FNWD vs PBYI Comparison
FNWD vs PBYI Comparison
Compare FNWD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWD
- PBYI
- Stock Information
- Founded
- FNWD 1994
- PBYI 2010
- Country
- FNWD United States
- PBYI United States
- Employees
- FNWD N/A
- PBYI N/A
- Industry
- FNWD Savings Institutions
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- FNWD Finance
- PBYI Health Care
- Exchange
- FNWD Nasdaq
- PBYI Nasdaq
- Market Cap
- FNWD 137.4M
- PBYI 126.5M
- IPO Year
- FNWD N/A
- PBYI N/A
- Fundamental
- Price
- FNWD $31.10
- PBYI $2.89
- Analyst Decision
- FNWD
- PBYI Strong Buy
- Analyst Count
- FNWD 0
- PBYI 1
- Target Price
- FNWD N/A
- PBYI $7.00
- AVG Volume (30 Days)
- FNWD 2.9K
- PBYI 215.1K
- Earning Date
- FNWD 10-29-2024
- PBYI 10-31-2024
- Dividend Yield
- FNWD 1.54%
- PBYI N/A
- EPS Growth
- FNWD N/A
- PBYI N/A
- EPS
- FNWD 3.07
- PBYI 0.18
- Revenue
- FNWD $70,040,000.00
- PBYI $219,143,000.00
- Revenue This Year
- FNWD N/A
- PBYI N/A
- Revenue Next Year
- FNWD N/A
- PBYI N/A
- P/E Ratio
- FNWD $10.14
- PBYI $15.47
- Revenue Growth
- FNWD N/A
- PBYI N/A
- 52 Week Low
- FNWD $17.29
- PBYI $2.13
- 52 Week High
- FNWD $33.05
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- FNWD 53.65
- PBYI 56.62
- Support Level
- FNWD $30.51
- PBYI $2.76
- Resistance Level
- FNWD $31.40
- PBYI $2.93
- Average True Range (ATR)
- FNWD 0.47
- PBYI 0.11
- MACD
- FNWD -0.23
- PBYI 0.02
- Stochastic Oscillator
- FNWD 23.90
- PBYI 76.92
About FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.